Korro Bio - רווח למניה בשנים עשר החודשים האחרונים KRRO

This EPS price chart illustrating value trends helps assess the implementation of the OPERA system strategy for mutation correction in alliance with Novo Nordisk. The current figure for Korro Bio, Inc. (KRRO) stands at 3.80, while the company's computing power and laboratories are fully utilized in current research. Business growth relies on a unique RNA editing method and promising developments in the therapy of liver pathologies.

The indicator is calculated as the percentage change in net income per share over a rolling year, based on the bottom-line items of the profit and loss statement. This metric determines the dynamics of real shareholder income, identifying business scaling rates or a stage of deep investment. For Korro Bio, Inc. (KRRO) and its OPERA platform, such fluctuations reflect the costs of developing safe RNA editing. By analyzing the annual growth of basic net income per share (TTM), an investor can distinguish fundamental growth from speculative surges.